RPRX

$67.181.90%1.25

Nachbörslich: 67.20+0.02 +0.03%

Royalty Pharma Plc (RPRX)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$65.93

Offen:

$67.00

24-Stunden-Volumen:

4,660,277

Relatives Volumen:

1.49

Marktkapitalisierung:

$29.91B

Einnahmen:

$2.44B

Nettoeinkommen (Verlust:

$1.36B

KGV:

35.19

EPS:

$1.91

Netto-Cashflow:

$574.14M

1W Leistung:

+5.20%

1M Leistung:

+15.11%

6M Leistung:

+34.12%

1Y Leistung:

+81.86%

1-Tages-Spanne:

$66.40$67.71

1-Wochen-Bereich:

$63.49$67.71

52-Wochen-Spanne:

$36.03$67.71

Royalty Pharma Plc Aktie (RPRX) Unternehmensprofil

Firmenname

Royalty Pharma Plc

Sektor

Healthcare

Branche

Biotechnology

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY, USA

Mitarbeiter

100

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

SEC

RPRX-Diskussionen auf X

RPRX vs. VRTX, REGN, MRNA, ARGX, ONC vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	$67.18	$29.91B	$2.44B	$1.36B	$574.14M	$1.91
VRTX Vertex Pharmaceuticals Inc	$558.88	$141.65B	$12.34B	$4.34B	$3.71B	$16.87
REGN Regeneron Pharmaceuticals Inc	$927.89	$95.53B	$14.92B	$4.42B	$3.79B	$41.04
MRNA Moderna Inc	$221.72	$88.52B	$2.23B	-$3.19B	-$1.60B	-$8.15
ARGX Argen X Se Adr	$892.87	$56.15B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$370.33	$41.89B	$5.76B	$514.49M	$1.10B	$4.48

Royalty Pharma Plc Aktie (RPRX) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-01-30	Hochstufung	UBS	Neutral → Buy
2025-09-30	Eingeleitet	Goldman	Buy
2025-05-16	Eingeleitet	Morgan Stanley	Overweight
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Resumed	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Resumed	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Royalty Pharma Plc-Aktie (RPRX) Insiderhandel

Urist MarshallOct 05 '26
Officer
Transaktion
Proposed Sale
Kosten
$57.10
#Aktien
4,126
Wert ($)
235,595
#Aktien Gesamt
0
Urist MarshallSep 28 '26
Officer
Transaktion
Proposed Sale
Kosten
$57.88
#Aktien
4,126
Wert ($)
238,813
#Aktien Gesamt
0
Urist MarshallSep 28 '26
EVP, Research & Investments
Transaktion
Sale
Kosten
$57.88
#Aktien
4,126
Wert ($)
238,813
#Aktien Gesamt
4,126
Hite ChristopherSep 22 '26
EVP & Chairman, Partnering
Transaktion
Sale
Kosten
$58.53
#Aktien
100,000
Wert ($)
5,853,095
#Aktien Gesamt
270,401
SCH Investment Partners LLCSep 22 '26
Officer
Transaktion
Proposed Sale
Kosten
$58.47
#Aktien
100,000
Wert ($)
5,846,972
#Aktien Gesamt
0
Hite ChristopherAug 18 '26
EVP & Chairman, Partnering
Transaktion
Sale
Kosten
$59.97
#Aktien
100,000
Wert ($)
5,997,250
#Aktien Gesamt
370,401
SCH Investment Partners LLCAug 18 '26
Officer
Transaktion
Proposed Sale
Kosten
$60.12
#Aktien
100,000
Wert ($)
6,012,000
#Aktien Gesamt
0
Coyne Terrance P.Aug 13 '26
EVP & CFO
Transaktion
Sale
Kosten
$58.68
#Aktien
11,002
Wert ($)
645,551
#Aktien Gesamt
0
Terrance CoyneAug 13 '26
Officer
Transaktion
Proposed Sale
Kosten
$58.56
#Aktien
11,002
Wert ($)
644,277
#Aktien Gesamt
0
Errol B. De SouzaAug 12 '26
Former Affiliate
Transaktion
Proposed Sale
Kosten
$57.79
#Aktien
206,352
Wert ($)
11,925,082
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Urist Marshall	Officer	Oct 05 '26	Proposed Sale	$57.10	4,126	235,595	0
Urist Marshall	Officer	Sep 28 '26	Proposed Sale	$57.88	4,126	238,813	0
Urist Marshall	EVP, Research & Investments	Sep 28 '26	Sale	$57.88	4,126	238,813	4,126
Hite Christopher	EVP & Chairman, Partnering	Sep 22 '26	Sale	$58.53	100,000	5,853,095	270,401
SCH Investment Partners LLC	Officer	Sep 22 '26	Proposed Sale	$58.47	100,000	5,846,972	0
Hite Christopher	EVP & Chairman, Partnering	Aug 18 '26	Sale	$59.97	100,000	5,997,250	370,401
SCH Investment Partners LLC	Officer	Aug 18 '26	Proposed Sale	$60.12	100,000	6,012,000	0
Coyne Terrance P.	EVP & CFO	Aug 13 '26	Sale	$58.68	11,002	645,551	0
Terrance Coyne	Officer	Aug 13 '26	Proposed Sale	$58.56	11,002	644,277	0
Errol B. De Souza	Former Affiliate	Aug 12 '26	Proposed Sale	$57.79	206,352	11,925,082	0

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

Oct 29, 2026

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Oct 29, 2026

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Oct 29, 2026

Oct 25, 2026

Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead - The Motley Fool

Oct 25, 2026

Oct 16, 2026

Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share - Quiver Quantitative

Oct 16, 2026

Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. - Stock Titan

Oct 16, 2026

Oct 15, 2026

Global femtech market to reach $255.5B by 2035, driven by AI, telehealth, and personalized women's healthcare. - Pluang

Oct 15, 2026

Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com India

Oct 12, 2026

Royalty Pharma EVP Marshall Urist sells $235,594 in shares - Investing.com

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com Nigeria

Oct 12, 2026

Royalty Pharma EVP Marshall Urist sells $235,594 in shares By Investing.com - Investing.com Nigeria

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com UK

Oct 12, 2026

Oct 08, 2026

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 08, 2026

Oct 05, 2026

At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan

Oct 05, 2026

Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares By Investing.com - Investing.com India

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC Filing - Form 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK

Sep 25, 2026

Sep 23, 2026